GALVUS NOVARTIS PDF

Novartis’ Galvus (vildagliptin) is a member of a new class of oral antidiabetic agents known as dipeptidyl peptidase IV inhibitors (DPP-IV) inhibitors or ‘incretin . Galvus Approval Status. FDA Approved: No Brand name: Galvus Generic name: vildagliptin. Previous Name: LAF Company: Novartis Pharmaceuticals. Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral.

Author: Taushicage Moogushicage
Country: Syria
Language: English (Spanish)
Genre: Career
Published (Last): 26 February 2006
Pages: 232
PDF File Size: 13.54 Mb
ePub File Size: 4.83 Mb
ISBN: 819-1-61748-817-7
Downloads: 23923
Price: Free* [*Free Regsitration Required]
Uploader: Kajizil

The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methotrimeprazine. For the full list of excipients, see section 6.

Acetylsalicylic acid Acetylsalicylic acid may increase the hypoglycemic activities of Vildagliptin. The risk or severity of hypoglycemia can be increased when Lipoic Acid is combined with Vildagliptin.

galvuw

Efonidipine The risk or severity of hypoglycemia can be increased when Efonidipine is combined with Vildagliptin. Veterinary regulatory Overview Research and development Marketing authorisation Post-authorisation. The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Vildagliptin. The risk or severity of angioedema can be increased when Forasartan is combined with Vildagliptin.

The risk or severity of hypoglycemia can be increased when Metformin is combined with Vildagliptin. Infections and infestations Very rare Upper respiratory tract infection Very rare Nasopharyngitis Metabolism and nutrition disorders Uncommon Hypoglycaemia Nervous system disorders Common Dizziness Uncommon Headache Vascular disorders Uncommon Oedema peripheral Gastrointestinal disorders Uncommon Constipation Musculoskeletal and connective tissue disorders Uncommon Galvuz.

The Journal of Galvuus Endocrinology and Metabolism. The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Vildagliptin. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Fasudil. Trovafloxacin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Trovafloxacin.

It must not be used in patients who have diabetic ketoacidosis high levels of ketones and acids in the blooddiabetic novartiz, problems with their kidneys or liver, conditions that may affect the kidneys, or a disease that causes a reduced supply of oxygen to the tissues such as failure of the heart or lungs or a recent heart attack. The risk or severity of angioedema can be increased when Vildagliptin is combined with Quinaprilat.

  BRITISH ANTI LEWISITE PDF

Brexpiprazole The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Brexpiprazole. Pramlintide The risk or severity of hypoglycemia can be increased when Pramlintide is combined with Vildagliptin.

The risk or severity of angioedema can be increased when Pregabalin is combined with Vildagliptin. Norfloxacin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Norfloxacin. Ceritinib The therapeutic efficacy of Vildagliptin can be decreased when used in movartis with Ceritinib.

Galvus (vildagliptin) FDA Approval Status –

Megestrol acetate The novsrtis efficacy of Vildagliptin can be decreased when used in combination with Megestrol acetate. Repaglinide The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Vildagliptin. Summary of the safety profile Safety data were obtained from a total of 3, patients exposed to vildagliptin at a daily dose of 50 mg once daily or mg 50 mg twice daily or mg once daily in controlled trials of at least 12 weeks duration.

However, the major hydrolysis metabolite LAY can be removed by haemodialysis. Phenoxypropazine Phenoxypropazine may increase the hypoglycemic activities of Vildagliptin. Mestranol The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Mestranol. The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Vildagliptin. Hypoglycaemia Sulphonylureas are known to cause hypoglycaemia.

Dexniguldipine The risk or severity of hypoglycemia can be increased when Dexniguldipine is combined with Vildagliptin. Dimetacrine Dimetacrine may decrease the hypoglycemic activities of Vildagliptin. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfadimethoxine.

  INCRUSTACIONES ONLAY INLAY PDF

Clinical efficacy and safety More than 15, patients with type 2 diabetes participated in double-blind placebo- or active-controlled clinical trials of up to nlvartis than 2 years’ treatment duration.

Galvus Approval Status

The therapeutic efficacy of Vildagliptin can be decreased when used noavrtis combination with Indapamide. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. Gastrointestinal symptoms, particularly soft faeces, mucoid faeces, diarrhoea and, at higher doses, faecal blood were observed in dogs.

Vildagliptin belongs to a class of orally active antidiabetic drugs DPP-IV inhibitors that appear to have multiple functional benefits beyond simple blood-glucose control.

Sulfaethoxypyridazine The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfaethoxypyridazine. Nandrolone Nandrolone may increase the hypoglycemic activities of Vildagliptin.

Vildagliptin launched by Novartis for dual therapy in type 2 diabetes

Acetazolamide The therapeutic efficacy of Vildagliptin can be increased when used in combination with Acetazolamide. Indalpine The risk or severity of hypoglycemia can be increased when Indalpine is combined with Vildagliptin.

Diabetes, Type 2 Galvus vildagliptin is a dipeptidyl peptidase 4 DPP-4 inhibitor intended for galgus as a once-daily oral treatment for patients with type 2 diabetes. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Everolimus. Insulin Pork Vildagliptin may increase the hypoglycemic activities of Insulin Pork.

The therapeutic efficacy of Vildagliptin can be increased when used in combination with Succinylsulfathiazole. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Galvuz. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Celecoxib.

Liver function should be monitored during treatment with Galvus at three-month intervals during the first year and periodically thereafter. Skin and subcutaneous tissue disorders.